In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
Xilio Therapeutics Inc (NASDAQ: XLO) closed the day trading at $0.64 down -0.88% from the previous closing price of $0.65. In other words, the price has decreased by -$0.88 from its previous closing price. On the day, 0.52 million shares were traded. XLO stock price reached its highest trading level at $0.655 during the session, while it also had its lowest trading level at $0.6305.
Upgrades & Downgrades
In the most recent recommendation for this company, Leerink Partners on August 06, 2025, initiated with a Outperform rating and assigned the stock a target price of $2.
On December 21, 2022, Chardan Capital Markets started tracking the stock assigning a Buy rating and target price of $7.
On January 10, 2022, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $36.H.C. Wainwright initiated its Buy rating on January 10, 2022, with a $36 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Jun 16 ’25 when Shannon James Samuel bought 45,000 shares for $0.69 per share. The transaction valued at 30,870 led to the insider holds 45,000 shares of the business.
Shannon James Samuel bought 25,000 shares of XLO for $17,215 on Jun 17 ’25. The Director now owns 70,000 shares after completing the transaction at $0.69 per share. On Jun 16 ’25, another insider, Russo Rene, who serves as the PRESIDENT AND CEO of the company, bought 36,289 shares for $0.68 each. As a result, the insider paid 24,680 and bolstered with 281,172 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, XLO now has a Market Capitalization of 43232948 and an Enterprise Value of -62895540. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.06. Its current Enterprise Value per Revenue stands at -1.978 whereas that against EBITDA is 1.491.
Stock Price History:
The Beta on a monthly basis for XLO is -0.03, which has changed by -0.43333334 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, XLO has reached a high of $1.70, while it has fallen to a 52-week low of $0.62. The 50-Day Moving Average of the stock is -10.23%, while the 200-Day Moving Average is calculated to be -13.10%.
Shares Statistics:
Over the past 3-months, XLO traded about 612.63K shares per day on average, while over the past 10 days, XLO traded about 335110 shares per day. A total of 51.83M shares are outstanding, with a floating share count of 22.95M. Insiders hold about 56.28% of the company’s shares, while institutions hold 16.33% stake in the company. Shares short for XLO as of 1767139200 were 2168608 with a Short Ratio of 3.54, compared to 1764288000 on 6675820. Therefore, it implies a Short% of Shares Outstanding of 2168608 and a Short% of Float of 5.96.
Earnings Estimates
The stock of Xilio Therapeutics Inc (XLO) is currently being evaluated by 1.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.14 and low estimates of -$0.14.
Analysts are recommending an EPS of between -$0.44 and -$0.44 for the fiscal current year, implying an average EPS of -$0.44. EPS for the following year is -$0.18, with 1.0 analysts recommending between -$0.18 and -$0.18.
Revenue Estimates
1 analysts predict $7.96M in revenue. The current quarter. It ranges from a high estimate of $7.96M to a low estimate of $7.96M. As of. The current estimate, Xilio Therapeutics Inc’s year-ago sales were $1.72MFor the next quarter, 1 analysts are estimating revenue of $6.9M. There is a high estimate of $6.9M for the next quarter, whereas the lowest estimate is $6.9M.
A total of 1 analysts have provided revenue estimates for XLO’s current fiscal year. The highest revenue estimate was $45.65M, while the lowest revenue estimate was $45.65M, resulting in an average revenue estimate of $45.65M. In the same quarter a year ago, actual revenue was $6.34MBased on 1 analysts’ estimates, the company’s revenue will be $81.75M in the next fiscal year. The high estimate is $81.75M and the low estimate is $81.75M.
